• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经调节蛋白-2,一种ErbB3/ErbB4受体酪氨酸激酶的新配体。

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.

作者信息

Carraway K L, Weber J L, Unger M J, Ledesma J, Yu N, Gassmann M, Lai C

机构信息

Department of Cell Biology, Harvard Medical School, Beth Israel Hospital, Boston, Massachusetts 02215, USA.

出版信息

Nature. 1997 May 29;387(6632):512-6. doi: 10.1038/387512a0.

DOI:10.1038/387512a0
PMID:9168115
Abstract

The neuregulins (NRGs) are a family of multipotent epidermal-growth-factor-like (EGF-like) factors that arise from splice variants of a single gene. They influence the growth, differentiation, survival and fate of several cell types. We have now discovered a set of new neuregulin-like growth factors, which we call neuregulin-2 (NRG-2): these are encoded by their own gene and exhibit a distinct expression pattern in adult brain and developing heart. Like NRG-1, the EGF-like domain of the new ligands binds to both the ErbB3- and ErbB4-receptor tyrosine kinases. However, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles from NRG-1. Our results indicate that NRG-1 and NRG-2 mediate distinct biological processes by acting at different sites in tissues and eliciting different biochemical responses in cells.

摘要

神经调节蛋白(NRGs)是一类多能的表皮生长因子样(EGF样)因子,由单个基因的剪接变体产生。它们影响多种细胞类型的生长、分化、存活和命运。我们现已发现一组新的神经调节蛋白样生长因子,我们将其称为神经调节蛋白-2(NRG-2):它们由各自的基因编码,并在成体脑和发育中的心脏中表现出独特的表达模式。与NRG-1一样,新配体的EGF样结构域与ErbB3和ErbB4受体酪氨酸激酶结合。然而,NRG-2刺激产生的ErbB受体酪氨酸磷酸化谱与NRG-1不同。我们的结果表明,NRG-1和NRG-2通过作用于组织中的不同位点并在细胞中引发不同的生化反应来介导不同的生物学过程。

相似文献

1
Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.神经调节蛋白-2,一种ErbB3/ErbB4受体酪氨酸激酶的新配体。
Nature. 1997 May 29;387(6632):512-6. doi: 10.1038/387512a0.
2
Ligands for ErbB-family receptors encoded by a neuregulin-like gene.由神经调节蛋白样基因编码的ErbB家族受体的配体。
Nature. 1997 May 29;387(6632):509-12. doi: 10.1038/387509a0.
3
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.神经调节蛋白-4:一种通过ErbB-4受体酪氨酸激酶发挥作用的新型生长因子。
Oncogene. 1999 Apr 29;18(17):2681-9. doi: 10.1038/sj.onc.1202631.
4
Bivalence of EGF-like ligands drives the ErbB signaling network.表皮生长因子样配体的二价性驱动着表皮生长因子受体(ErbB)信号网络。
EMBO J. 1997 Aug 15;16(16):4938-50. doi: 10.1093/emboj/16.16.4938.
5
Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression.神经调节蛋白集中在神经肌肉突触处,并激活乙酰胆碱受体基因的表达。
Nature. 1995 Jan 12;373(6510):158-61. doi: 10.1038/373158a0.
6
Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.β细胞ulin激活表皮生长因子受体和erbB-4,并诱导出与表皮生长因子或神经调节蛋白-β刺激所产生的不同的细胞反应模式。
Oncogene. 1996 Jan 18;12(2):345-53.
7
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.致癌性表皮生长因子受体2/表皮生长因子受体3异二聚体是表皮生长因子和β细胞素的替代受体。
Oncogene. 1998 Mar 12;16(10):1249-58. doi: 10.1038/sj.onc.1201642.
8
ErbB kinases and NDF signaling in human prostate cancer cells.人前列腺癌细胞中的表皮生长因子受体(ErbB)激酶与神经分化因子(NDF)信号传导
Oncogene. 1997 Nov 27;15(22):2705-16. doi: 10.1038/sj.onc.1201447.
9
A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells.一种含有两个卵泡抑素模块的新型表皮生长因子样分子可刺激MKN28胃癌细胞中erbB-4的酪氨酸磷酸化。
Biochem Biophys Res Commun. 1999 Dec 20;266(2):593-602. doi: 10.1006/bbrc.1999.1873.
10
Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.神经调节蛋白受体 ErbB3 在小鼠心脏中的表达、定位和调控。
J Cell Physiol. 2011 Feb;226(2):450-5. doi: 10.1002/jcp.22354.

引用本文的文献

1
Down-regulation of neuregulin2 (NRG2) following spinal cord injury in C57BL/6 mice: Its implications in therapeutic potential.C57BL/6小鼠脊髓损伤后神经调节蛋白2(NRG2)的下调:其在治疗潜力方面的意义。
Iran J Basic Med Sci. 2025;28(8):1075-1081. doi: 10.22038/ijbms.2025.83787.18131.
2
Short-term overloading exercise attenuates articular chondrocyte features partly via synovium-cartilage interactions mediated by inhibin subunit beta A.短期超负荷运动部分通过抑制素亚基βA介导的滑膜-软骨相互作用减弱关节软骨细胞特征。
Sci Rep. 2025 Feb 25;15(1):6772. doi: 10.1038/s41598-025-91742-1.
3
Transcriptomic Response of the Ovarian Follicle Complex in Post-Vitellogenic Rainbow Trout to 17α,20β-Dihdroxy-4-pregnen-3-one In Vitro.
卵黄生成后期虹鳟卵巢卵泡复合体对17α,20β - 二羟基 - 4 - 孕烯 - 3 - 酮的体外转录组反应
Int J Mol Sci. 2024 Nov 26;25(23):12683. doi: 10.3390/ijms252312683.
4
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.新辅助化疗前后三阴性乳腺癌肿瘤的基因组和转录组分析
Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7.
5
Discovery of NRG1-VII: the myeloid-derived class of NRG1.发现 NRG1-VII:NRG1 的髓系类。
BMC Genomics. 2024 Aug 29;25(1):814. doi: 10.1186/s12864-024-10723-2.
6
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review.HER2 阳性乳腺癌中的 HER2/PI3K/AKT 通路:综述。
Medicine (Baltimore). 2024 Jun 14;103(24):e38508. doi: 10.1097/MD.0000000000038508.
7
Neuregulin 2 Is a Candidate Gene for Autism Spectrum Disorder.神经调节蛋白 2 是孤独症谱系障碍的候选基因。
Int J Mol Sci. 2024 May 19;25(10):5547. doi: 10.3390/ijms25105547.
8
The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.一氧化氮对癌症中HER家族翻译后修饰及下游信号传导的影响。
Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024.
9
Expert Consensus on the Diagnosis and Treatment of Gene Fusion Solid Tumors.基因融合实体瘤诊断与治疗专家共识
Glob Med Genet. 2024 Feb 27;11(1):86-99. doi: 10.1055/s-0044-1781457. eCollection 2024 Jan.
10
Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.荧光原位杂交在筛查 NRG1 基因重排方面存在局限性。
Diagn Pathol. 2024 Jan 3;19(1):1. doi: 10.1186/s13000-023-01424-7.